Study on Sunitinib for Patients with Metastatic Kidney Cancer Resistant to Cytokine Treatment
Sponsor: Pfizer
ClinicalTrials ID:NCT00130897
This study provides access to the drug Sunitinib for patients with metastatic kidney cancer who cannot join other Sunitinib clinical trials but may benefit from the treatment.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The main goal of this study is to offer the drug Sunitinib to patients with metastatic renal cell carcinoma (RCC) who cannot participate in other ongoing Sunitinib clinical trials. The decision to provide this treatment is based on the doctor's assessment that the patient may benefit from it.
Description
This study is part of an Expanded Access program, which means it is not a traditional clinical trial with control groups. Therefore, it does not require the same level of results reporting as other clinical trials. The study is registered on ClinicalTrials.gov, but detailed results will not be posted. The purpose of this program is to make Sunitinib available to patients who have metastatic kidney cancer and have not responded to cytokine treatments, offering them a potential treatment option when other clinical trials are not suitable.
Eligibility Criteria
Inclusion Criteria
- Have kidney cancer that cannot be treated with standard therapies aimed at curing the disease.
Exclusion Criteria
- Currently participating in another clinical trial for treatment.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.